Rockwell Medical (RMTI) Stock Forecast & Price Target

Rockwell Medical is benefiting from renewed listing stability after its 1-for-10 reverse stock split, which helped the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement and removed an overhang on the equity. Operationally, 2Q26 revenue of $17.8M rose 11% year over year, driven by new Western U.S. customers and stronger orders from existing dialysis providers, reinforcing demand for its hemodialysis concentrate portfolio. Despite a wider-than-expected net loss of $0.34 per share, the company ended the midpoint of 2026 with $24.8M in cash, cash equivalents, and marketable securities and generated $2.1M in free cash flow from operations, supporting a constructive outlook.

Rockwell Medical is challenged by a valuation that rests on only about $74M of enterprise value against roughly $24M to $25M of cash and $8.7M to $9M of debt, suggesting limited cushion if execution slips. The core bearish case centers on its reliance on market traction and partnerships in a competitive dialysis supply market, where commercial setbacks or weak adoption could quickly pressure growth. In addition, management’s inability to control expenses and the possibility of medium- to long-term equity dilution create further downside risk, especially given the low terminal growth assumption of 1% and the sensitivity of the DCF to share count changes by end-1Q27 or mid-2027.